How has Venture Interest in Medical Devices Evolved?

Sean Gilligan, Chief Operating Officer at AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease discusses his years of experience in the medical device field and how it has evolved and talks about hospitals evaluating their tech investments in a tight economy.

Sean Gilligan is the Chief Operations Officer of AVS Pulse. Before joining AVS, Sean spent 15 years as Vice President of Program Management, R&D at Boston Scientific. In this role, he oversaw the expanded Interventional Cardiology portfolio and acted as the direct leader of the project management team across multiple sites responsible for products including coronary stents, PTCA accessories, Watchman and the TAVR structural heart valves franchise. He led transformational high growth product development and project execution efforts in the $2+ billion Interventional Cardiology business and was responsible for managing budgets over $100 million and enabling multiple global launches for Class III PMA (pre market approval) and 510(k) products. Prior to his role as VP of Program Management, R&D, Mr. Gilligan held several positions at Boston Scientific, including Director of Program Management, R&D Manager, R&D Engineering and Manufacturing Engineering. In total he brings over 30 years of medical device experience to AVS. Mr. Gilligan holds a Bachelor of Science in Mechanical Engineering from University College Dublin and an MBA from the Oxford Brookes University.